BACKGROUND: The aim of the study was to investigate the role of the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) G6230A variant on the susceptibility of latent autoimmune diabetes in adults (LADA) as a whole and in the subset of patients who share autoimmune thyroid disease (AITD). METHODS: The study included 202 LADA, 1373 patients with early onset type 1 diabetes (T1D), 130 patients with late-onset T1D, 188 patients with non-autoimmune diabetes and 1904 healthy controls. Thyrotropin (thyrotropin-stimulating hormone; TSH) and antibodies against thyroid peroxidase were analyzed in all patients. The CTLA4 G6230A variant was assessed in LADA, early and late-onset T1D patients as well as in the controls. RESULTS: The frequency of CTLA4 G alleles and genotypes in LADA patients did not differ significantly from that in the other groups, regardless of its association with AITD. We found an increased frequency of G allele-containing genotypes within LADA patients who had higher TSH compared with those with normal TSH (P = 0.002). Moreover, LADA patients carrying G allele-containing genotypes were more likely to require insulin therapy within 4 years of diagnosis (P = 0.002). CONCLUSIONS: The G6230A CTLA4 variant does not confer susceptibility to LADA in Sardinian patients even when associated with AITD. However, it helps identify a particular subset of LADA patients with more clinically severe disease, both for thyroid dysfunction and diabetes.
BACKGROUND: The aim of the study was to investigate the role of the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) G6230A variant on the susceptibility of latent autoimmune diabetes in adults (LADA) as a whole and in the subset of patients who share autoimmune thyroid disease (AITD). METHODS: The study included 202 LADA, 1373 patients with early onset type 1 diabetes (T1D), 130 patients with late-onset T1D, 188 patients with non-autoimmune diabetes and 1904 healthy controls. Thyrotropin (thyrotropin-stimulating hormone; TSH) and antibodies against thyroid peroxidase were analyzed in all patients. The CTLA4G6230A variant was assessed in LADA, early and late-onset T1D patients as well as in the controls. RESULTS: The frequency of CTLA4 G alleles and genotypes in LADA patients did not differ significantly from that in the other groups, regardless of its association with AITD. We found an increased frequency of G allele-containing genotypes within LADA patients who had higher TSH compared with those with normal TSH (P = 0.002). Moreover, LADA patients carrying G allele-containing genotypes were more likely to require insulin therapy within 4 years of diagnosis (P = 0.002). CONCLUSIONS: The G6230ACTLA4 variant does not confer susceptibility to LADA in Sardinian patients even when associated with AITD. However, it helps identify a particular subset of LADA patients with more clinically severe disease, both for thyroid dysfunction and diabetes.
Authors: Giovanni Mario Pes; Alessandro Palmerio Delitala; Alessandra Errigo; Giuseppe Delitala; Maria Pina Dore Journal: Intern Emerg Med Date: 2015-11-26 Impact factor: 3.397
Authors: Magdalena Niegowska; Alessandro Delitala; Giovanni Mario Pes; Giuseppe Delitala; Leonardo A Sechi Journal: PLoS One Date: 2017-05-04 Impact factor: 3.240
Authors: Thiago P Muniz; Daniel V Araujo; Kerry J Savage; Tina Cheng; Moumita Saha; Xinni Song; Sabrina Gill; Jose G Monzon; Debjani Grenier; Sofia Genta; Michael J Allen; Diana P Arteaga; Samuel D Saibil; Marcus O Butler; Anna Spreafico; David Hogg Journal: Cancers (Basel) Date: 2021-12-24 Impact factor: 6.639
Authors: Alessandro P Delitala; Giovanni M Pes; Hoda M Malaty; Gavino Pisanu; Giuseppe Delitala; Maria P Dore Journal: J Diabetes Res Date: 2015-12-28 Impact factor: 4.011